Heat Biologics Stock News

In last trading session, Heat Biologics Inc. (NASDAQ:HTBX) saw 0.32 million shares changing hands with its beta currently measuring 0.23. Companys recent per share price level of $3.93 trading at -$0.24 or -5.76% at ring of the bell on the day assigns it a market valuation of $99.63M. That closing price of HTBXs stock is Heat Biologics Inc. (NASDAQ:HTBX) -13.44% Down Over A Week, Can The Stock Hit Well Above -$0.61? Read More »

Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations

Designed for rapid plug and play programming and stockpiling against emerging infectious agents and viral mutations

Squarepoint Ops LLC acquired a new stake in Heat Biologics, Inc. (NASDAQ:HTBX) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 18,807 shares of the biopharmaceutical companys stock, valued at approximately $127,000. Other large investors have also recently bought and sold shares of the company. Morgan Stanley increased its stake in shares of Heat Biologics []

Heat Biologics, Inc. (NASDAQ:HTBX) was the target of a large decline in short interest in the month of October. As of October 29th, there was short interest totalling 1,720,000 shares, a decline of 17.3% from the October 14th total of 2,080,000 shares. Based on an average daily trading volume, of 254,300 shares, the short-interest ratio []

Analysts forecast that Heat Biologics, Inc. (NASDAQ:HTBX) will announce earnings per share of ($0.30) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Heat Biologics earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.31). The firm is expected to report its next quarterly earnings report on Wednesday, []

DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate

DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune s

DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune s

Conference call scheduled for September 2nd at 11:00 AM ET Conference call scheduled for September 2nd at 11:00 AM ET

Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discover

Developing a new era of precision medicines using a unique and proprietary drug discovery platform Developing a new era of precision medicines using a unique and proprietary drug discovery platform

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate

DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate

Groundbreaking ceremony to be streamed live Groundbreaking ceremony to be streamed live